Analysts at StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a report issued on Saturday. The firm set a “sell” rating on the stock.
Trinity Biotech Stock Up 2.8 %
Shares of NASDAQ:TRIB opened at $0.69 on Friday. Trinity Biotech has a twelve month low of $0.63 and a twelve month high of $3.55. The stock’s 50 day moving average is $0.79 and its 200-day moving average is $1.14. The firm has a market capitalization of $12.53 million, a price-to-earnings ratio of -0.31 and a beta of 1.20.
Institutional Investors Weigh In On Trinity Biotech
A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its stake in shares of Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 5.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 378,590 shares of the company’s stock after buying an additional 18,780 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent quarter. Institutional investors and hedge funds own 78.97% of the company’s stock.
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Recommended Stories
- Five stocks we like better than Trinity Biotech
- How to Plot Fibonacci Price Inflection Levels
- FedEx Delivers Another Crushing Blow to Its Stock Price
- How to Use the MarketBeat Excel Dividend Calculator
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- Following Congress Stock Trades
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
